Menisoxoisoaporphine A, a Novel Oxoisoaporphine Alkaloid from Menispermi Rhizoma, Inhibits Inflammation by Targeting PDE4B

Overview

Journal Front Pharmacol

Date 2024 Dec 18

PMID 39691395

Authors

Xin Qiao

Xiaojuan Cao

Shuang Xu

Cunlin Wang

Rui Guo

Xiaojuan Yao

Qiong Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Dysregulated and excessive inflammatory reactions can lead to tissue damage, which is the underlying cause of most human diseases. Menisoxoisoaporphine A (MA), a novel oxoisoaporphine alkaloid, was obtained from Menispermi Rhizoma, a traditional Chinese medicinal herb used in the treatment of inflammatory conditions in clinical practice. This suggests that MA has very promising potential for the development of anti-inflammatory therapeutics. Hence, this study aims to investigate the anti-inflammatory effects and underlying mechanisms of MA.

Method: The anti-inflammatory effects of MA were evaluated in lipopolysaccharide (LPS)-induced mouse macrophage RAW264.7 cells. Its underlying mechanisms were explored through RNA sequencing and Western blotting. The binding modes and interactions sites between MA and phosphodiesterase 4B (PDE4B) were predicted using molecular docking and validated by molecular dynamics simulation.

Results: MA treatment significantly reduced LPS-induced morphological changes, inflammatory cytokine relesae, and proinflammatory genes expression in RAW264.7 cells compared to the LPS-induced controls. Transcriptome sequencing analysis suggested that PDE4B might be a key target for MA to exert its therapeutic effect. Mechanismly, MA directly acted on Tyr405 site of PDE4B, thus leading to a sustained elevation of the cyclic adenosine monophosphate (cAMP) levels, which subsequently inactivated NF-κB signaling pathway by phosphorylating protein kinase A (PKA). MA inhibited the NF-κB-mediated inflammatory response depending on PDE4B.

Conclusion: MA, a natural and novel compound, exerted anti-inflammatory effects in LPS-induced RAW264.7 macrophage cells. It demonstrated a strong binding ability to the Tyr405 sites of PDE4B, thereby inhibiting NF-κB signaling pathway by regulating the cAMP-PKA axis. Elucidating the interaction between MA and PDE4B holds significant potential for the advancement of innovative therapeutic strategies aimed at inflammatory diseases. By strategically modulating this interaction, it may be feasible to achieve more precise regulation of inflammatory responses, thereby offering promising therapeutic benefits for conditions such as rheumatoid arthritis, asthma, and inflammatory bowel disease.

References

Luan X, Cong Z, Anastassiades T, Gao Y . -Butyrylated Hyaluronic Acid Achieves Anti-Inflammatory Effects In Vitro and in Adjuvant-Induced Immune Activation in Rats. Molecules. 2022; 27(10). PMC: 9145605. DOI: 10.3390/molecules27103267. View

Wang J, Wolf R, Caldwell J, Kollman P, Case D . Development and testing of a general amber force field. J Comput Chem. 2004; 25(9):1157-74. DOI: 10.1002/jcc.20035. View

Wade S, Trenkmann M, McGarry T, Canavan M, Marzaioli V, Wade S . Altered expression of microRNA-23a in psoriatic arthritis modulates synovial fibroblast pro-inflammatory mechanisms via phosphodiesterase 4B. J Autoimmun. 2018; 96:86-93. DOI: 10.1016/j.jaut.2018.08.008. View

Wan Q, Xu C, Zhu L, Zhang Y, Peng Z, Chen H . Targeting PDE4B (Phosphodiesterase-4 Subtype B) for Cardioprotection in Acute Myocardial Infarction via Neutrophils and Microcirculation. Circ Res. 2022; 131(5):442-455. DOI: 10.1161/CIRCRESAHA.122.321365. View

Han R, Xiao Y, Bai Q, Choi C . Self-therapeutic metal-based nanoparticles for treating inflammatory diseases. Acta Pharm Sin B. 2023; 13(5):1847-1865. PMC: 10213990. DOI: 10.1016/j.apsb.2022.07.009. View

Yan J, Zhang Y, Yu H, Zong Y, Wang D, Zheng J . GPSM1 impairs metabolic homeostasis by controlling a pro-inflammatory pathway in macrophages. Nat Commun. 2022; 13(1):7260. PMC: 9700814. DOI: 10.1038/s41467-022-34998-9. View

Schepers M, Paes D, Tiane A, Rombaut B, Piccart E, Veggel L . Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis. Brain Behav Immun. 2022; 109:1-22. DOI: 10.1016/j.bbi.2022.12.020. View

Schafer P . Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012; 83(12):1583-90. DOI: 10.1016/j.bcp.2012.01.001. View

Pearse D, Hughes Z . PDE4B as a microglia target to reduce neuroinflammation. Glia. 2016; 64(10):1698-709. DOI: 10.1002/glia.22986. View

10.

Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C . Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019; 25(12):1822-1832. PMC: 7147972. DOI: 10.1038/s41591-019-0675-0. View

11.

Trott O, Olson A . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009; 31(2):455-61. PMC: 3041641. DOI: 10.1002/jcc.21334. View

12.

Hedde J, Hanks A, Schmidt C, Hughes Z . The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammation. Brain Behav Immun. 2017; 64:285-295. DOI: 10.1016/j.bbi.2017.04.015. View

13.

Li H, Zuo J, Tang W . Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol. 2018; 9:1048. PMC: 6199465. DOI: 10.3389/fphar.2018.01048. View

14.

He Y, Huang Y, Mai C, Pan H, Luo H, Liu L . The immunomodulatory role of PDEs inhibitors in immune cells: therapeutic implication in rheumatoid arthritis. Pharmacol Res. 2020; 161:105134. DOI: 10.1016/j.phrs.2020.105134. View

15.

OBoyle N, Banck M, James C, Morley C, Vandermeersch T, Hutchison G . Open Babel: An open chemical toolbox. J Cheminform. 2011; 3:33. PMC: 3198950. DOI: 10.1186/1758-2946-3-33. View

16.

Bai D, Sun T, Lu F, Shen Y, Zhang Y, Zhang B . Eupatilin Suppresses OVA-Induced Asthma by Inhibiting NF-κB and MAPK and Activating Nrf2 Signaling Pathways in Mice. Int J Mol Sci. 2022; 23(3). PMC: 8836136. DOI: 10.3390/ijms23031582. View

17.

Li H, Fan C, Feng C, Wu Y, Lu H, He P . Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity. Br J Pharmacol. 2019; 176(13):2209-2226. PMC: 6555859. DOI: 10.1111/bph.14667. View

18.

Crilly A, Robertson S, Reilly J, Gracie J, Lai W, Leung B . Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane. Ann Rheum Dis. 2011; 70(6):1130-7. DOI: 10.1136/ard.2010.134825. View

19.

van der Spoel D, van Maaren P . The Origin of Layer Structure Artifacts in Simulations of Liquid Water. J Chem Theory Comput. 2015; 2(1):1-11. DOI: 10.1021/ct0502256. View

20.

Yang W, Wang Y, Wang T, Li C, Shi L, Zhang P . Protective effects of IRG1/itaconate on acute colitis through the inhibition of gasdermins-mediated pyroptosis and inflammation response. Genes Dis. 2023; 10(4):1552-1563. PMC: 10311025. DOI: 10.1016/j.gendis.2022.05.039. View